MM&M Awards: Who's Going to Shine in 2009

Despite an increasingly difficult environmental for healthcare marketers, the MM&M Awards program continues to grow in size, stature and relevance—as evidenced by last year's record-breaking 830 submissions. So why such a clamor to win gold? It's because this program is judged fairly, independently and with the authority of a large panel of industry experts. We go to extraordinary lengths to make sure that the best work wins. Just ask a seasoned judge:

“Many areas of marketing communications are highly subjective, more art than science,” says Joe Shields, product director for Enbrel at Wyeth. “However, the judges for the MM&M Awards do their level best to assess fairly entries based on objective criteria and business impact, when provided. I continue to serve as a judge (three times so far) because it is a valuable part of my continuing marketing education. I can count on a few entries each year that make me say, ‘Wow, I wish I had done that!'”
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.